Candida albicans UPC2 gene: Insights into its structure, function, and impact on azole resistance, a mini-review

Document Type : Reviews

Authors

1 Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Student Research Committee, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran

2 Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

3 Department of Basic Medical Sciences, Shoushtar Faculty of Medical Sciences, Shoushtar, Iran

4 Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran

5 Invasive Fungi Research Centre (IFRC), Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

6 Invasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran. Department of Medical Mycology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

7 Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

8 Infectious Diseases Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran & Department of Medical Parasitology and Mycology, School of Medicine, Kermanshah University of Medical Sciences,

9 Infectious Diseases Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran. Department of Physiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran

10 Department of Medical Mycology and Invasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. Department of Medical Mycology, Faculty of Medicine, Mazandaran University of Medical

10.22034/cmm.2025.345323.1595

Abstract

Background and Purpose: Candidiasis is a prevalent fungal infection caused by various species of Candida, especially, C. albicans. The emergence of resistance to azole medications, which are frequently prescribed for the treatment of Candida infections, presents a significant challenge in the management of these infections.
Materials and Methods: The present mini-review summarizes findings from a comprehensive search of articles published between 1999 and 2024, retrieved from Scopus, PubMed, and Web of Science. Studies were selected using specific keywords based on relevance to UPC2 gene functions, azole resistance mechanisms, and C. albicans biology.
Results: The UPC2 gene has become crucial in regulating drug resistance in C. albicans. This gene encodes a zinc (II)-Cys (6) transcription factor involved in the biosynthesis of sterols and contributes to resistance against azole antifungal drugs. When exposed to azoles, UPC2 in C. albicans enhances the expression of ergosterol biosynthesis genes, such as ERG2 and ERG11. Increased expression of ERG11 leads to reduced susceptibility to azoles by boosting the production of 14α-lanosterol demethylase, the primary target of these antifungal agents. Furthermore, UPC2 regulates sterol uptake under anaerobic conditions and manages other adaptations to environmental changes, all of which contribute to azole resistance.
Conclusion: Gaining insight into how the UPC2 gene contributes to azole resistance is essential for the development of effective strategies in the antifungal drug development process.

Keywords

Main Subjects

References

  1. Denning DW. Global incidence and mortality of severe fungal disease. Lancet Infect Dis. 2024;24(7):e428-e438.
  2. Soriano A, Honore PM, Puerta-Alcalde P, Garcia-Vidal C, Pagotto A, Gonçalves-Bradley DC, Verweij PE. Invasive candidiasis: current clinical challenges and unmet needs in adult populations. J Antimicrob Chemother. 2023;78(7):1569-1585.
  3. Lass-Flörl C, Kanj SS, Govender NP, Thompson III GR, Ostrosky-Zeichner L, Govrins MA. Invasive candidiasis. Nat Rev Dis Primers. 2024;10(1):20.
  4. Kaushik N, Pujalte GG, Reese ST. Superficial Fungal Infections. Prim Care. 2015;42(4):501-16.
  5. Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN, editors. Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997–2016. Open forum infectious diseases; 2019;6(Suppl-1):S79-S94.
  6. Arastehfar A, Gabaldón T, Garcia-Rubio R, Jenks JD, Hoenigl M, Salzer HJ, et al. Drug-resistant fungi: an emerging challenge threatening our limited antifungal armamentarium. Antibiotics. 2020;9(12):877.
  7. Dougue AN, El‐Kholy MA, Giuffrè L, Galeano G, D′ Aleo F, Kountchou CL, et al. Multilocus sequence typing (MLST) analysis reveals many novel genotypes and a high level of genetic diversity in Candida tropicalis isolates from Italy and Africa. Mycoses. 2022;65(11):989-1000.
  8. Organization WH. WHO fungal priority pathogens list to guide research, development and public health action: World Health Organization; 2022.
  9. van Rhijn N, Arikan-Akdagli S, Beardsley J, Bongomin F, Chakrabarti A, Chen SC, et al. Beyond bacteria: the growing threat of antifungal resistance. The Lancet. 2024;404(10457):1017-1018.
  10. Rabaan AA, Sulaiman T, Al-Ahmed SH, Buhaliqah ZA, Buhaliqah AA, AlYuosof B, et al. Potential Strategies to Control the Risk of Antifungal Resistance in Humans: A Comprehensive Review. Antibiotics. 2023; 12(3):608.
  11. Nishimoto AT, Sharma C, Rogers PD. Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans. J Antimicrob Chemother. 2020;75(2):257-70. doi: 10.1093/jac/dkz400.
  12. Gong Y, Li T, Yu C, Sun S. Candida albicans heat shock proteins and Hsps-associated signaling pathways as potential antifungal targets. Front Cell Infect Microbiol. 2017;7:520.
  13. Xiang M-J, Liu J-Y, Ni P-H, Wang S, Shi C, Wei B, et al. Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans. FEMS Yeast Res. 2013;13(4):386-93.
  14. Joshua IM, Höfken T. From Lipid Homeostasis to Differentiation: Old and New Functions of the Zinc Cluster Proteins Ecm22, Upc2, Sut1 and Sut2. Int J Mol Sci. 2017;18(4):772.
  15. Candida Genome database.2024.
  16. Davari A, Haghani I, Hassanmoghadam F, Nabili M, Shokohi T, Hedayati MT, et al. Echinocandin resistance in Candida parapsilosis sensu stricto: Role of alterations in CHS3, FKS1 and Rho gene expression. J Glob Antimicrob Resist. 2020;22:685-8.
  17. MacPherson S, Akache B, Weber S, De Deken X, Raymond M, Turcotte B. Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes. Antimicrob Agents Chemother. . 2005;49(5):1745-1752.
  18. Silver Peter M, Oliver Brian G, White Theodore C. Role of Candida albicans Transcription Factor Upc2p in Drug Resistance and Sterol Metabolism. Eukaryotic Cell. 2004;3(6):1391-7.
  19. Czajka KM, Venkataraman K, Brabant-Kirwan D, Santi SA, Verschoor C, Appanna VD, et al. Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Cells. 2023;12(22):2655.
  20. Rodrigues Marcio L. The Multifunctional Fungal Ergosterol. mBio. 2018;9(5):e01755-18.
  21. Dunkel N, Liu TT, Barker KS, Homayouni R, Morschhäuser J, Rogers PD. A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans Eukaryot Cell. 2008;7(7):1180–1190.
  22. Schubert S, Barker KS, Znaidi S, Schneider S, Dierolf F, Dunkel N, et al. Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicans. Antimicrob Agents Chemother. 2011;55(5):2212-23.
  23. Znaidi S, Weber S, Al-Abdin OZ, Bomme P, Saidane S, Drouin S, et al. Genomewide location analysis of Candida albicans Upc2p, a regulator of sterol metabolism and azole drug resistance. Eukaryot Cell. 2008;7(5):836-47.
  24. Vasicek Erin M, Berkow Elizabeth L, Flowers Stephanie A, Barker Katherine S, Rogers PD. UPC2 Is Universally Essential for Azole Antifungal Resistance in Candida albicans. Eukaryotic Cell. 2014;13(7):933-46.
  25. Fattouh N, Hdayed D, Hijazi A, Tokajian S, Khalaf RA. UPC2 mutations and development of azole resistance in Candida albicans hospital isolates from Lebanon. J Glob Antimicrob Resist. 2024;38:341-348.
  26. Kakade P, Mahadik K, Balaji KN, Sanyal K, Nagaraja V. Two negative regulators of biofilm development exhibit functional divergence in conferring virulence potential to Candida albicans. FEMS Yeast Res. 2018;19(2).
  27. Ha S, Tong J, Yang H, Youn HS, Eom SH, Im YJ. Crystallization and preliminary X-ray crystallographic analysis of sterol transcription factor Upc2 from Saccharomyces cerevisiae. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2013;69(Pt 2):147-152.
  28. Yang H, Tong J, Lee CW, Ha S, Eom SH, Im YJ. Structural mechanism of ergosterol regulation by fungal sterol transcription factor Upc2. Nature Communications. 2015;6(1):6129.
  29. Flowers SA, Barker KS, Berkow EL, Toner G, Chadwick SG, Gygax SE, et al. Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans. Eukaryot Cell. 2012;11(10):1289-1299.
  30. Rosam K, Monk BC, Lackner M. Sterol 14α-Demethylase Ligand-Binding Pocket-Mediated Acquired and Intrinsic Azole Resistance in Fungal Pathogens. Journal of fungi (Basel, Switzerland). 2020;7(1).
  31. Stenkiewicz-Witeska JS, Ene IV. Azole potentiation in Candida PLoS pathogens. 2023;19(8):e1011583.
  32. Heilmann CJ, Schneider S, Barker KS, Rogers PD, Morschhäuser J. An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans. Antimicrob Agents Chemother. 2010;54(1):353-359.
  33. Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. Azole antifungal resistance in Candida albicans and emerging non-albicans Candida Front microbiol. 2017;7:231851.
  34. Khojasteh S, Jafarzdeh J, Hosseini SA, Haghani I, Turki H, Aghaei Gharehbolagh S, et al. Candida auris and COVID-19: A health threatening combination. Curr Med Mycol. 2022;8(3):44-50.
  35. Li J, Aubry L, Brandalise D, Coste AT, Sanglard D, Lamoth F. Upc2-mediated mechanisms of azole resistance in Candida auris. Microbiol Spectr. 2024;12(2):e03526-23.
  36. Hoot SJ, Smith AR, Brown RP, White TC. An A643V amino acid substitution in Upc2p contributes to azole resistance in well-characterized clinical isolates of Candida albicans. Antimicrob Agents Chemother. 2011;55(2):940-942.
  37. Popp C, Hampe IAI, Hertlein T, Ohlsen K, Rogers PD, Morschhäuser J. Competitive Fitness of Fluconazole-Resistant Clinical Candida albicans Antimicrob Agents Chemother. 2017;61(7).e00584-17.
  38. Sasse C, Dunkel N, Schäfer T, Schneider S, Dierolf F, Ohlsen K, Morschhäuser J. The stepwise acquisition of fluconazole resistance mutations causes a gradual loss of fitness in C andida albicans. Mol Microbiol. 2012;86(3):539-556.
  39. Morio F, Pagniez F, Besse M, Gay-Andrieu F, Miegeville M, Le Pape P. Deciphering azole resistance mechanisms with a focus on transcription factor-encoding genes TAC1, MRR1 and UPC2 in a set of fluconazole-resistant clinical isolates of Candida albicans. Int J Antimicrob Agents. 2013;42(5):410-415.
  40. Sitterlé E, Coste AT, Obadia T, Maufrais C, Chauvel M, Sertour N, et al. Large-scale genome mining allows identification of neutral polymorphisms and novel resistance mutations in genes involved in Candida albicans resistance to azoles and echinocandins. J Antimicrob Chemother. 2020;75(4):835-848.
  41. Khalaf RA, Fattouh N, Medvecky M, Hrabak J. Whole genome sequencing of a clinical drug resistant Candida albicans isolate reveals known and novel mutations in genes involved in resistance acquisition mechanisms. J Med Microbiol. 2021;70(4).
  42. Pristov K, Ghannoum M, Fidsa. Resistance of Candida to azoles and echinocandins worldwide. Clin Microbiol Infect. 2019;25. doi: 10.1016/j.cmi.2019.03.028.
  43. Selmecki A, Forche A, Berman J. Genomic plasticity of the human fungal pathogen Candida albicans. Eukaryotic cell. 2010;9(7):991-1008.
  44. O’Brien CE, Oliveira-Pacheco J, Ó Cinnéide E, Haase MA, Hittinger CT, Rogers TR, et al. Population genomics of the pathogenic yeast Candida tropicalis identifies hybrid isolates in environmental samples. PLoS pathogens. 2021;17(3):e1009138.

 

Current Medical Mycology
Volume 10, Continuous
2024
Pages 1-7

Files

History

  • Receive Date: 27 November 2024
  • Revise Date: 29 December 2024
  • Accept Date: 08 January 2025
  • Publish Date: 01 January 2025

Share

How to cite

Statistics